Delhi's pollution continues to worsen, and every day, there is new data on its AQI levels, suggesting the conditions Delhiites are living in, unable to breathe, go out, and much more. In fact, 60.3% of Delhi-NCR residents have sought pollution-related medical assistance last year, showed a survey by SmyttenPulseAI. The number is severe and points towards a healthcare crisis in the making.

The survey also showed that 80% of residents reported experiencing persistent health issues, which included chronic cough, debilitating fatigue, and respiratory irritation due to polluted air.

How Was The Study Conducted?

It was a study that surveyed 4,000 residents across Delhi, Gurugram, Noida, Ghaziabad, and Faridabad and found that 76.4% of respondents have drastically reduced outdoor time. This means they have turned their homes into the only place of solace, often like virtual prisons for families to hide from the toxic air outside.

The survey also found that 79.8% of the residents are either reconsidering their stay or have already left, with 33.6% planning their departure, while 31% are actively considering relocating, and 15.2% have already relocated.

Why the relocation? s Dr Rahul Chawla, a neurologist trained at AIIMS, who, on his Instagram, posted a video where he suggested that if people can afford, and their profession allows, they must leave Delhi for a few weeks. “Because this city has become a gas chamber,” he warned.

The survey is a reflection of the same thought, with 37% residents who have already taken concrete steps of visiting properties in nearby cities. They have enquired for schools, or have made family decisions about leaving. The preferred destination for most are: hilly areas, small towns with fewer factories, and anywhere outside Delhi-NCR that does not mean to continuous keep an eye on AQI monitor app while breathing, as reported by NDTV.

The report said pollution has added a heavy economic burden on middle-class families, with 85.3 per cent noticing higher household expenses because of it. Among them, 41.6 per cent said the financial strain has been significant.

If You Cannot Leave Delhi, Here's What You Can Do

Stay Indoors

Dr Chawla suggested that one should stay indoors as much as possible. "You can open the windows and doors only between 1 and 3pm in the day, when you feel that the sun is bright, so that the house gets proper ventilation," he said.

Why 1pm to 3pm is the only time he suggests to have exposure with air? As per a 2023 study by an air filter brand, Delhi's air pollution peaked at 9AM and gradually improved as the day progressed. On an average, Delhi sees roughly as half as much PM2.5 by 5PM. Similarly, in Kolkata, the pollution peaks at 8am and is lowered by 4PM. This is why the safest time to have any sort of air exposure is in the afternoon. Pollution levels also tend to be slightly lower in the afternoon because it is when the sun is at its peak. This heats the ground and causes warm air to rise and mix with atmosphere. This helps disperse pollutants.

He also advised against cleaning inside the house using a dry cloth, and suggested wet cloth to be in use, so that dust does not rise. "Please do not light up things inside the house like burning dhoop (incense for worship), agarbatti (incense sticks), or anything else that causes excessive smoke,” he said.

Use N95 Mask

“If there are elderly people at home, do not let them go for morning walks or evening walks, and if there are children, do not let them play in the park. Exercise at home. You can go up and down the stairs. You can do yoga. If you have a treadmill or a stationary bike at home, you can exercise with it. You can do weightlifting,” he said. However, he suggested that if going out is absolutely necessary, then one must wear N-95 mask properly before stepping out.

Air Purifier

“If you can afford an air purifier, buy one. But keep in mind that the air purifier you are buying should be appropriate for the size of your room,” the neurologist advised.

Work From Home

The neurologist also suggested that if your company permits it, seek work from home option to reduce your exposure from toxic air.

Ozempic, Wegovy, Saxenda, Trulicity, Mounjaro, all from different brands, with different active ingredient but all are GLP-1-type drugs, which have now been linked with depression, suicidal thoughts, and changes in mood and behavior. As a result, the Therapeutic Goods Administration (TGA), Australia released a safety alert on Monday to update the product warnings of GLP-1-type drugs.

This is to "ensure consistent information regarding the potential risk of suicidal thoughts or behaviours". The alert said, "The updates follow investigations by TGA and other international regulators. Patients taking any of these medicines should tell their health professional if they experience new or worsening depression, suicidal thoughts or any unusual changes in mood or behaviour."

While the TGA noted that not enough evidences were there to conclude the drugs caused such changes however, there is indeed a complex relationship between mental illness and conditions GLP-1 drug treat, that could be associated with suicidal thoughts, which cannot be ignored.

GLP-1 Drugs Sold In Australia

• Ozempic (semaglutide)
• Wegovy (semaglutide)
• Saxenda (liraglutide)
• Trulicity (dulaglutide)
• Mounjaro (tirzepatide)

Weight Loos Drugs For Women

The TGA has issued a separate warning about a possible link between the GLP-1 drug tirzepatide, sold as Mounjaro, and reduced effectiveness of oral contraceptives. The regulator said it cannot rule out the possibility that the medication may interfere with how well oral birth control works. As a precaution, product information for tirzepatide has been updated to include clearer advice for patients who rely on the pill.

According to the TGA, women who are taking tirzepatide should consider switching to a non-oral contraceptive or using an additional barrier method for four weeks after starting the medicine. The same advice applies for four weeks after each time the dose is increased.

The alert also reminded patients that GLP-1 medications should not be used during pregnancy.

What Are GLP-1 Drugs And How Do They Work?

GLP-1 drugs have become widely known for helping people manage type 2 diabetes and obesity. They work by copying the action of a natural hormone that slows digestion and helps people stay full for longer. Their popularity has skyrocketed over the past few years, but there has also been ongoing discussion about their potential mental health effects.

Some studies overseas have suggested that people with anxiety or depression might face a higher risk of depression, anxiety or suicidal thoughts when taking these medications.

The US Food and Drug Administration has been reviewing reports of suicidal thoughts among people using GLP-1 drugs. So far, the agency says it has not found evidence that the medications directly cause these thoughts, although it notes that the number of cases is small and it cannot completely rule out a possible risk.

The TGA highlighted similar concerns in its safety update. The agency has received 72 reports of suicidal thoughts from people taking GLP-1 drugs, along with a smaller number of reports involving suicide, attempted suicide or depression-related suicide.

With an estimated half a million Australians now using these medicines, the regulator launched a detailed review and sought advice from the Advisory Committee on Medicines. The committee concluded that the available evidence does not support a clear link between GLP-1 drugs and suicidal or self-harming behaviour. However, it recommended updating product information to ensure consistency and to promote awareness without suggesting a proven causal connection.

Eli Lilly announced a significant reduction in cash princes of its popular weight loss drug, Zepbound, which are sold through its direct to consumer platform, LillyDirect. This move will expand the ongoing efforts by both the company and the Trump administration to make obesity and diabetes medications for affordable for Americans.

The announcement comes right after its rival Novo Nordisk decided to introduce additional cash price discounts on its popular obesity and diabetes drugs.

What Is In For Patients? New, Lower Monthly Costs

Starting Monday, patients who pay cash and have a valid prescription can purchase Zepbound’s starting-dose single-dose vials for as low as $299 per month, reduced from the previous $349. The next dose, 5 milligrams, will cost $399 per month, while all higher doses will now be $449 per month, down from $499.

These discounts are substantial considering Zepbound’s list price of about $1,086 per month. Combined with inconsistent insurance coverage for weight-loss medications in the U.S., the high list price has long posed an access barrier for many patients.

Push To Expand Access of Weight Loss And Diabetes Drugs For Those Who Need It

The price cuts come on the heels of President Donald Trump’s recently signed agreements with Eli Lilly and Novo Nordisk. These deals aim to make GLP-1 drugs, widely used for weight loss and Type 2 diabetes, more affordable and accessible.

Under the agreements, the government will pay reduced prices for the medications, Medicare will for the first time cover obesity drugs for certain patients, and Americans will be able to purchase discounted doses through the government’s upcoming direct-to-consumer platform, TrumpRx, launching in January, 2026.

However, the Trump–Eli Lilly agreement focuses specifically on lowering future prices for multi-dose pen versions of Zepbound after they receive FDA approval. That makes Monday’s announcement especially meaningful: patients can benefit immediately from discounted pricing on the currently available single-dose vials.

Eli Lilly emphasized its commitment to widening access to obesity treatments. “We will keep working to provide more options, expanding choices for delivery devices and creating new pathways for access—so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities.

How Does Zepbound Work?

Zepbound is a dual agonist, targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-action approach activates two pathways that amplify insulin secretion, slow gastric emptying, and reduce appetite, ultimately aiding in weight loss. Intresitngly, this drug was linked ot other benefits besides weight loss. Research has found that Zepbound may also offer additional health benefits, including improved cardiovascular health and potential effects on obstructive sleep apnea.

The results of the clinical trials were published on Dec 4. It showed that participants taking Zepbound lost an average of 50.3 lbs, compared to 33.1 lbs with Wegovy. Moreover, nearly 32% of those on Zepbound achieved at least a 25% reduction in body weight, while only 16.1% of Wegovy users reached this milestone.

However, the efficacy of these medicines are variable for different individual. Health experts have repeatedly cautioned that individual responses to each medication can differ. Factors such as medical history and body composition play a role in how well a person responds to these medications, so one may be more effective than the other for certain individuals.

President Donald Trump said on Sunday that he is ready to make public the results of a Magnetic Resonance Imaging (MRI) scan he underwent in October, a test that has prompted questions from political opponents and medical observers. The President also admitted he did not know which part of his body the imaging focused on.

While speaking to reporters aboard the flight back to Washington after a visit to his Mar-a-Lago residence in Florida, Trump addressed the matter of the medical report. The scan was conducted during his second physical examination of the year at Walter Reed National Military Medical Center. He said he had no objection to sharing the records and told the press, “If you want to have it released, I’ll release it.”

Trump MRI Raises Questions About Routine Testing

President Donald Trump said that he is ready to make public the results of an MRI scan he underwent in October. The White House has repeatedly maintained that his overall health remains strong. Press Secretary Karoline Leavitt has said before that the 79-year-old president received “advanced imaging” as part of his “routine physical examination,” and that the full assessment showed he stayed in “exceptional physical health.”

Still, Trump’s own remarks brought an unexpected angle to the discussion. When asked what the scan was meant to check, he described the procedure as standard. He told reporters, “Getting an MRI is very standard. What, you think I shouldn’t have it? Other people get it. I had an MRI.” He added that the findings were “perfect,” and repeated his doctors’ comment that it was “the best result he has ever seen as a doctor.”

Although he spoke with confidence about the results, he could not explain what the scan was intended to examine. “I have no idea what they analyse, but whatever they analyse, they analysed it well and they said that I had as good a result as they’ve ever seen,” he said. He did make one point clear: “It wasn’t the brain because I took a cognitive test and I aced it.”

Trump MRI Disclosure Sparks Fresh Political Debate

News of the MRI has revived debate over Trump’s willingness to share information about his health, as MRIs are not usually part of a routine annual evaluation. They are generally recommended when doctors need to study issues involving the brain, spine, or heart. The October appointment at Walter Reed followed another physical only a few months earlier and came at a time when there were reports of chronic venous insufficiency, adding to scrutiny of his health status.

Trump MRI and His Known Medical Condition

Earlier this year, the White House confirmed that Trump has chronic venous insufficiency (CVI), a vascular condition in which the veins in the legs have difficulty sending blood back to the heart. This problem can lead to swelling and discomfort.

On October 10, Trump returned to Walter Reed National Military Medical Center. Leavitt described the visit as a “routine annual check-up,” although it was his second such trip in six months. Dr. Sean Barbabella, the White House physician, did not offer details on the imaging or preventive screenings done during the appointment. He did say that the President’s laboratory reports were “exceptional,” and that his cardiac profile suggested a biological age nearly 14 years younger than his actual one.

On October 27, Trump disclosed that he had undergone an unspecified MRI during an earlier visit to Walter Reed. He said the scan produced “some of the best reports for the age” and “some of the best reports they’ve ever seen,” but the absence of further explanation has added to questions regarding his health.

Trump has also spoken before about taking the Montreal Cognitive Assessment (MoCA), a screening tool used to detect cognitive decline. He has often described it as a “very difficult IQ test.” It is not clear if another MoCA was completed during the October visit or if he was referring to the ones taken in April 2025 or January 2018.